Objective To investigate the efficacy of ziprasidone combined with valproate in the treatment of bipolar manic episodes and its effect on serum three iodine thyroprodine (T3) and brain derived neurotrophic factor (BDNF). Methods A total of 98 patients with bipolar disorder manic episodes in Zhongshan Third Peopleʼs hospital from February 2016 to May 2018 were selected as the subjects. These patients were randomly divided into olanzapine group (n=49) and ziprasidone group (n=49). The patients in the olanzapine group were administrated with olanzapine combined with sodium valproate, while patients in the ziprasidone group were given ziprasidone combined with sodium valproate. After 8-week treatment, the level of serum T3 and BDNF and mania score were measured. Results After treatment, T3 and BDNF in both groups were higher than those before treatment, and ziprasidone group was higher than olanzapine group (P<0.05). After treatment, the scores of manic symptoms in both groups were lower than those before treatment, and ziprasidone group was lower than olanzapine group (P<0.05). Conclusion Ziprasidone combined with valproate sodium is effective in the treatment of bipolar manic attack, which may improve the levels of serum T3 and BDNF in patients.%目的 探讨齐拉西酮结合丙戊酸钠治疗双相障碍躁狂发作对血清三碘甲状腺原氨酸(T3)和脑源性神经营养因子(BDNF)的影响.方法 选取2017年2月—2018年5月期间在中山市第三人民医院接受治疗的双相障碍躁狂发作患者98例为研究对象.采用数表法将患者随机分为齐拉西酮组和奥氮平组,每组各49例.奥氮平组患者采用丙戊酸钠缓释片联合奥氮平治疗,齐拉西酮组患者采用丙戊酸钠缓释片联合齐拉西酮治疗,治疗8周后,比较两组患者治疗前后T3和BDNF水平、躁狂评分.结果 两组患者治疗后T3、BDNF均较治疗前升高,且齐拉西酮组高于奥氮平组(P<0.05).两组患者治疗后躁狂症状评分均较治疗前降低,且齐拉西酮组低于奥氮平组(P<0.05).结论 齐拉西酮联合丙戊酸钠治疗双相障碍躁狂发作,疗效确切,同时改善患者T3和BDNF水平,具有一定的临床应用价值.
展开▼
